|  |  |
| --- | --- |
| **Variables** | **N (%)** |
|
| **No. patients (%)** | 195 (100%) |
|   |   |
| **Race, n (%)** |  |
| Caucasian | 175 (89.7%) |
| African-American | 17 (8.7%) |
| Other | 2 (1.0%) |
| Unknown | 1 (0.5%) |
| **Patient age, yr** |  |
| Median (Q1, Q3) | 59 (56-64) |
| **Preoperative PSA (ng/mL)** |  |
| Median (Q1, Q3) | 8.8 (6-14.9) |
| **RP Gleason Score, n (%)** |  |
| ≤3+4 | 82 (42.1%) |
| 4+3 | 29 (14.9%) |
| 8 | 22 (11.3%) |
| ≥9 | 62 (31.8%) |
| **Extraprostatic Extension, n (%)** |  |
|   | 152 (77.9%) |
| **Seminal Vesicle Invasion, n (%)** |  |
|   | 60 (30.8%) |
| **Positive Surgical Margins, n (%)** |  |
|   | 73 (37.4%) |
| **Lymph Node Invasion, n (%)** |  |
|   | 48 (24.6%) |
| **Follow-up of censored patients post-BCR, yr** |  |
| Median (Q1, Q3) | 5 (3-8) |

**Supplementary Table S5. Demographic and clinical characteristics of eligible patients undergoing radical prostatectomy in post-biochemical recurrence cohort**